Wire · operational-macro
ARPA-H takes aim at decade-long drug development with SURPASS trial overhaul
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
The US Department of Health and Human Services, via ARPA-H, launched the SURPASS program to transform clinical trial design and execution with simulation, real-time analysis, and automation, aiming to reduce drug development timelines from over ten years to under four. Complementary projects focus on accelerating site activation, privacy-preserving consent, and patient data contribution to modernize US clinical development.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
Drug developers must prepare for new trial methods that could redefine regulatory evidence generation and slash trial times. You need to start testing adaptive designs and digital twins now to stay ahead in the US market.
◆ Coverage
2 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics